Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 24 2023 - 7:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
March 24, 2023
(Commission File No. 001-38475)
ASLAN PHARMACEUTICALS LIMITED
(REG. NO. 289175)
(Translation of registrant’s name into English)
CAYMAN ISLANDS
(Jurisdiction of incorporation or organization)
3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes No
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes No
Announcement of fourth quarter and full year 2022 financial results and corporate update
On March 24, 2023, ASLAN Pharmaceuticals Limited issued a press release announcing the financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
ASLAN PHARMACEUTICALS LIMITED |
(Registrant) |
|
|
By: |
/s/ Kiran Kumar Asarpota |
Name: |
Kiran Kumar Asarpota |
Title: |
Chief Operating Officer |
Date: March 24, 2023
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
From Dec 2024 to Jan 2025
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
From Jan 2024 to Jan 2025
